Sanofi Profit Hit By Falling Diabetes Revenue
February 09 2016 - 2:40AM
Dow Jones News
PARIS—French drugmaker Sanofi SA on Tuesday reported sharply
lower fourth-quarter net profit, hit by growing pricing pressure in
the U.S. diabetes market and higher accounting charges.
The Paris-based pharmaceutical company said net profit fell 75%
to €334 million ($374 million) for the three months through
December from €1.34 billion a year earlier.
Business net income, the company's term for adjusted income
excluding the impact of acquisitions and divestments, declined 6.5%
to €1.71 billion, above analysts' expectations of €1.65 billion.
Sanofi's total sales rose 2.3% to €9.28 billion.
Sanofi's earnings this quarter highlight the continuing
deterioration of the drugmaker's diabetes business in the U.S.,
where it is forced to offer larger discounts to the government,
insurers and health-care providers to push its products to the
market.
Diabetes drug sales, which account for about 20% of the
company's revenue, fell 13% to €1.9 billion in the fourth-quarter,
hurt by lower sales of its insulin drug Lantus, which lost patent
protection in the U.S. last year. However, Genzyme, Sanofi's
biotech unit, posted a 28% increase in revenue to €1.01 billion,
boosted by sales of multiple sclerosis treatment Aubagio. Sales of
consumer health care products rose 1% to €809 million, while
vaccines sales increased 15% to €1.44 billion.
Sanofi proposed a dividend of €2.93 a share on 2015
earnings.
In a bid to revive growth, Sanofi said last year it planned to
focus on fewer markets where it has or can build a competitive
position.
In December, the company said it had entered exclusive
negotiations with Boehringer Ingelheim GmbH on a possible exchange
of its animal-health business for most of the German group's
consumer-health-care unit.
Boehringer would pay Sanofi €4.7 billion as part of the deal.
Sanofi's animal-health business has an enterprise value of €11.4
billion and Boehringer's consumer-health-care business has an
enterprise value of €6.7 billion. The deal would make Sanofi the
global revenue leader in over-the-counter medicines, just ahead of
Bayer AG and GlaxoSmithKline PLC, and would make closely held
Boehringer No. 2 in animal health after Zoetis Inc.
Sanofi said it expected its business earnings per share to
remain "broadly stable" in 2016 at constant exchange rates,
"barring unforeseen major adverse events."
Write to Noemie Bisserbe at noemie.bisserbe@wsj.com
(END) Dow Jones Newswires
February 09, 2016 03:25 ET (08:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024